| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 16, 2021 | IP : Diurnal Group plc - Alkindi® approved by Swissmedic for use in Switzerland | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric AI
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, annou... |
| Nov 16, 2021 | Diurnal : Alkindi® approved by Swissmedic for use in Switzerland | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric AI
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, annou... |
| Nov 15, 2021 | IP : Diurnal Group plc - Directorate Changes | Appointment of Chairman and two Non-Executive Directors with extensive industry experience to support commercial growth
Anders Härfstrand, Deborah Jorn, and Jean-Michel Cosséry will join the Board with immediate effect
Diurnal Group plc (AI... |
| Oct 11, 2021 | Diurnal : Phase 1 data for DITEST™ published in European Journal of Endocrinology | US IND submission for the Company's third novel product expected in Q4 2021
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the results from... |
| Oct 11, 2021 | IP : Diurnal Group plc - Phase 1 data for DITEST published in EJE | US IND submission for the Company's third novel product expected in Q4 2021
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the results from... |
| Sep 14, 2021 | IP : Diurnal Group plc - Results for the year ended 30 June 2021 | Significant progress made during the year with two major regulatory approvals
Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits
Post-period, launch of Efmody® in Europe, Diurnal's second product ... |
| Sep 14, 2021 | Diurnal : Full Year Results for the year ended 30 June 2021 | Results for the year ended 30 June 2021
Significant progress made during the year with two major regulatory approvals
Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits
Post-period, launch of Efmo... |
| Sep 13, 2021 | Diurnal : Commercial launch of Efmody® in the UK | Commercial launch of Efmody® in the UK
Follows recent European launch in Germany and Austria
Provides a new treatment option for adult and adolescent patients suffering from CAH in the UK
Diurnal Group plc (AIM: DNL), the specialty pharmace... |
| Sep 13, 2021 | IP : Diurnal Group plc - Commercial launch of Efmody® in the UK | Follows recent European launch in Germany and Austria
Provides a new treatment option for adult and adolescent patients suffering from CAH in the UK
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs ... |
| Sep 1, 2021 | IP : Diurnal Group plc - Diurnal launches Efmody® in Germany and Austria | Represents Diurnal's second marketed product in Europe
Provides a new treatment option for adult and adolescent patients suffering from CAH
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chroni... |
| Sep 1, 2021 | Diurnal : launches Efmody® in Germany and Austria | Diurnal launches Efmody® in Germany and Austria
Represents Diurnal's second marketed product in Europe
Provides a new treatment option for adult and adolescent patients suffering from CAH
Diurnal Group plc (AIM: DNL), the specialty pharmace... |
| Aug 19, 2021 | IP : Diurnal Group plc - Full Year Results Investor Presentation | Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that Martin Whitaker, Chief Executive Officer, and Richard Bungay, Chief Financial Officer,... |
| Jul 28, 2021 | IP : Diurnal Group plc - Business and trading update | Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits
Efmody® European commercial preparations well-progressed with first market launch in Q3 2021
Efmody® US Phase 3 CAH study on track to commence in... |
| Jul 12, 2021 | IP : Diurnal Group plc - Diurnal receives agreement from US FDA on Special Protocol Assessment for Chronocort® | Pivotal Phase 3 trial expected to commence in the US in H2 2021
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that the US Food and Drug A... |
| Jul 12, 2021 | Diurnal : receives Special Protocol Assessment Agreement for Chronocort® from the FDA | Pivotal Phase 3 trial expected to commence in the US in H2 2021
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that the US Food and Drug A... |
| Jul 2, 2021 | IP : Diurnal Group plc - Diurnal receives Marketing Authorisation for Efmody® in Great Britain from the MHRA | Efmody® provides a new treatment option for c.5,000 patients suffering from CAH in GB
GB launch of Efmody® expected in Q1 2022
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (... |
| Jul 2, 2021 | Diurnal : receives Marketing Authorisation for Efmody® in Great Britain from the MHRA | Efmody® provides a new treatment option for c.5,000 patients suffering from CAH in GB
GB launch of Efmody® expected in Q1 2022
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (... |
| Jun 29, 2021 | Diurnal : Distribution agreement with Er-Kim for Bulgaria and Romania | Extends relationship with Er-Kim following Turkey agreement for Alkindi ® and Efmody®
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has... |
| Jun 29, 2021 | IP : Diurnal Group plc - Distribution agreement with Er-Kim for Bulgaria and Romania | Extends relationship with Er-Kim following Turkey agreement for Alkindi® and Efmody®
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has ... |
| Jun 1, 2021 | IP GROUP PLC
IP : Diurnal Group plc - Diurnal triggers $1.25m in milestone payments from Citrine Medicine | Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has triggered payments totalling $1.25 million from Citrine Medicine, Inc. ('Citrine'), i... |
| Jun 1, 2021 | DIURNAL GROUP PLC
Diurnal : triggers $1.25m in milestone payments from Citrine Medicine | Diurnal triggers $1.25m in milestone payments from Citrine Medicine
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has triggered payment... |
| May 28, 2021 | IP GROUP PLC
IP : Diurnal Group plc - Diurnal receives European Commission approval for Efmody® | First licensed treatment for European patients with CAH that mimics the physiological circadian rhythm of cortisol
Diurnal's second product to receive marketing authorisation
Commercial launch anticipated in Q3 2021
Diurnal Group plc (AIM: ... |
| May 12, 2021 | IP GROUP PLC
IP : Diurnal Group plc - China licensing agreement with Citrine Medicine for Efmody® | Partnership extended with China-based rare disease therapeutics company
Total up-front payment and future milestones of up to $29.75 million, with double-digit royalties on sales
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical co... |
| Apr 23, 2021 | IP GROUP PLC
IP : Diurnal Group plc - Grant of second European Patent for Alkindi® | Grant of second European Patent for Alkindi®
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the grant of a patent for Alkindi® (hydrocortisone g... |
| Apr 21, 2021 | IP GROUP PLC
IP : Diurnal Group plc - Proposed Placing, Subscription and Open Offer | Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces a proposed conditional Placing of Placing Shares with institutional investors and a Subscri... |
| Apr 21, 2021 | IP : Diurnal Group plc - Proposed Placing, Subscription and Open Offer | Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces a proposed conditional Placing of Placing Shares with institutional investors and a Subscri... |
| Mar 19, 2012 | Diurnal Raises £335K in Funding | Diurnal, a Cardiff, UK-based developer of a novel approach to drug delivery designed to help patients suffering from reduced levels of the key hormone cortisol (hydrocortisone), has raised £335k in financing.
Following the funding, Fusion I... |
| Dec 9, 2009 | UK, Diurnal Receives £600,000 Investment from Fusion IP and Finance Wales | Diurnal, an early stage company from the University of Sheffield, has received a £600,000 investment from Fusion IP (AIM: FIP) and Finance Wales.
Cardiff, Wales-based Diurnal is developing a novel approach to drug delivery which will help p... |
